HIV vaccine and human trials

HIV vaccine trials carried out on human subject indicated an anti-HIV immune system response in tests on 393 people in a study in Lancet. The vaccine has the potential of providing immunity against virous strains of the virus.
In a randomized, double-blind, placebo-controlled trials, a combination of mosaic vaccine was administered to healthy participants aged 18-50. The participants, from the US, Rwanda, Uganda, South Africa, and Thailand, received four vaccinations over the course of 48 weeks. All of the vaccine combinations produced an anti-HIV immune system response and were found to be safe.